Delivery of drugs to the eye remains a significant challenge for drug formulation scientists. While topical eye drops are the most convenient type of formulation for delivery to the eye, they are generally restricted to delivery to the anterior segment of the eye and are poorly suited for delivery to the posterior segment of the eye. Targeted delivery to the posterior aspect of the eye (vitreous humor or retina) is impeded by a number of ocular barriers, and drug delivery to the posterior of the eye has been identified as a key unmet need in ophthalmology.
The theme of this program aims to design, formulate and characterize novel drug delivery formulations that are capable of targeting not only the anterior segment of the eye (for diseases such as glaucoma), but also the posterior segment of the eye, for diseases such as age-related macular degeneration and diabetic retinopathy. Other potential targets include delivery of medications able to decrease intra-ocular pressures as a means of treating myopia.